According to the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) guidelines, there are other first-line treatment options for NSCLC harboring ROS1 rearrangement [13,14]. Here, ROS1 is linked to non-small cell lung carcinoma.